Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection-Reference-Cited by-同舟云学术

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Published:2018-01-25 Issue:4 Volume:378 Page:354-369
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Zeuzem Stefan¹,Foster Graham R.¹,Wang Stanley¹,Asatryan Armen¹,Gane Edward¹,Feld Jordan J.¹,Asselah Tarik¹,Bourlière Marc¹,Ruane Peter J.¹,Wedemeyer Heiner¹,Pol Stanislas¹,Flisiak Robert¹,Poordad Fred¹,Chuang Wan-Long¹,Stedman Catherine A.¹,Flamm Steven¹,Kwo Paul¹,Dore Gregory J.¹,Sepulveda-Arzola Gladys¹,Roberts Stuart K.¹,Soto-Malave Ruth¹,Kaita Kelly¹,Puoti Massimo¹,Vierling John¹,Tam Edward¹,Vargas Hugo E.¹,Bruck Rafi¹,Fuster Francisco¹,Paik Seung-Woon¹,Felizarta Franco¹,Kort Jens¹,Fu Bo¹,Liu Ran¹,Ng Teresa I.¹,Pilot-Matias Tami¹,Lin Chih-Wei¹,Trinh Roger¹,Mensa Federico J.¹

Affiliation:

1. From Goethe University Hospital, Frankfurt (S.Z.), and Medizinische Hochschule Hannover, Hannover (H.W.) — both in Germany; Queen Mary University of London, Barts Health, London (G.R.F.); AbbVie, North Chicago (S.W., A.A., J.K., B.F., R.L., T.I.N., T.P.-M., C.-W.L., R.T., F.J.M.), and Northwestern Feinberg School of Medicine, Chicago (S.F.) — both in Illinois; Liver Unit, Auckland City Hospital, Auckland (E.G.), and Christchurch Hospital and University of Otago, Christchurch (C.A.S.) — both in New...

Funder

AbbVie

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1702417

Cited by 375 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Results from a retrospective case finding and re-engagement exercise for people previously diagnosed with hepatitis C virus to increase uptake of directly acting antiviral treatment;BMC Public Health;2024-09-06

2. Real-World Data on the Use of Glecaprevir/Pibrentasvir in the Treatment of Hepatitis C: Is Shorter Treatment Possible?;Viral Hepatitis Journal;2024-08-28

3. Hepatitis C treatment outcome among people in prison: The SToP‐C study;Liver International;2024-08-27

4. Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review;Expert Opinion on Pharmacotherapy;2024-08-12

5. A COMPARISON OF SOFOSBUVIR/VELPATASVIR (S/V) AND GLECAPREVIR/PIBRENTASVIR (G/P) FOR THE TREATMENT OF HCV INFECTION AMONG HCV-INFECTED PEOPLE WHO USE DRUGS (PWUD);Journal of Virus Eradication;2024-08